SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (IMMIMMP ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced that clinical data on the Company's lead product candidate eftilagimod alpha ("efti" or "IMP321"), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism, will be presented at two industry conferences in October and November 2019.
| Conference: | World Immunotherapy Congress as part of Festival of Biologics 2019 |
| Dates: | October 15-17, 2019 (Tuesday, 15th October/ 2.50 p.m. CET) |
| Venue: | Basel Congress Centre, Basel, Switzerland |
| Presentation Title: | A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): a new combination in immuno-oncology – mature results of TACTI-mel |
| Presenter: | Frédéric Triebel, CSO & CMO of Immutep |
| Conference: | 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) |
| Dates: | November 6-10, 2019 (Friday, November 8th, 7.00am – 8.00pm EST) |
| Venue: | Gaylord National Hotel & Convention Center in National Harbor, 201 Waterfront St, Forest Heights, MD 20745, USA |
| Title: | Initial results from a Phase II study (TACTI-002) in non-small cell lung cancer, or head and neck cancer patients receiving eftilagimod alpha (LAG-3 fusion protein) and pembrolizumab |
| Poster Number: | 343 |
| Authors: | J. Peguero, E. Felip, B. Doger, M. Marjem, E. Carcereny, T. Clay, P. Bajaj, M. Krebs, F. Triebel |
All presentations will be made available on the Company's website at http://www.immutep.com/investors-media/presentations.html
About Immutep
Further information can be found on the Company's website www.immutep.com or by contacting:
U.S. Investors:
Jay Campbell, Chief Business Officer, Immutep Limited
+1 (917) 860-9404; jay.campbell@immutep.com
Garth Russell, LifeSci Advisors
+1 (646) 876-3613; garth@lifesciadvisors.com
Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
